Back
Sarepta Therapeutics, Inc. Stock Predictions
Exxon and Chevron Have an Unlikely New Competitor
DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at
Sell
50
SRPT
Sarepta Therapeutics, Inc.
Last Price:
$23.13
Seasonality Move:
6.84%
7 Day Trial
ALL ACCESS PASS
$
7
Meet America's Newest $1B Unicorn
DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available atSarepta Therapeutics, Inc. Stock Forecast
-
Over the next 52 weeks, Sarepta Therapeutics, Inc. has on average historically risen by 27.1% based on the past 28 years of stock performance.
-
Sarepta Therapeutics, Inc. has risen higher in 13 of those 28 years over the subsequent 52-week period, corresponding to a historical accuracy of 46.43%
-
Is Sarepta Therapeutics, Inc. Stock Undervalued?The current Sarepta Therapeutics, Inc. [SRPT] share price is $23.46. The Score for SRPT is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.
-
SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
Will Sarepta Therapeutics, Inc. Stock Go Up Next Year?
-
Over the next 52 weeks, Sarepta Therapeutics, Inc. has on average historically risen by 27.1% based on the past 28 years of stock performance.
Sarepta Therapeutics, Inc. Stock Rating
Sell
50
Sarepta Therapeutics, Inc. (SRPT)
is a Sell
Is Sarepta Therapeutics, Inc. overpriced?
-
Sarepta Therapeutics, Inc. has risen higher in 13 of those 28 years over the subsequent 52-week period, corresponding to a historical accuracy of 46.43%
Sarepta Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
sarepta.com
52-Week Data
52-Week High:
128.75
52-Week Low:
10.42
Prediction Charts
Market Cap:
2.5B
Price in USD:
23.46
Volume:
3.3M
Beta:
1.01
Technical Analysis
SMA50:
20.65
SMA100:
20.31
SMA200:
28.26
52-Wk Change:
-81.16%
Stock Predictions
-
Is Sarepta Therapeutics, Inc. stock public?Yes, Sarepta Therapeutics, Inc. is a publicly traded company.
-
What is the Sarepta Therapeutics, Inc. stock quote today?The Sarepta Therapeutics, Inc. stock price is 23.46 USD today.
-
How to buy Sarepta Therapeutics, Inc. stock online?You can buy Sarepta Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Dec-17 | 22.29 | 21.14 | 22.42 | 21.06 |
| Dec-18 | 21.15 | 20.34 | 21.64 | 20.14 |
| Dec-19 | 20.33 | 21.04 | 21.48 | 20.33 |
| Dec-22 | 20.87 | 21.23 | 21.53 | 20.86 |
| Dec-23 | 21.19 | 22.00 | 22.52 | 21.10 |
| Dec-24 | 21.96 | 22.32 | 22.46 | 21.82 |
| Dec-26 | 22.36 | 22.12 | 22.41 | 21.86 |
| Dec-29 | 21.81 | 21.82 | 21.96 | 21.36 |
| Dec-30 | 21.79 | 21.49 | 21.91 | 21.40 |
| Dec-31 | 21.45 | 21.52 | 21.77 | 21.33 |
| Jan-2 | 21.92 | 21.31 | 22.00 | 21.20 |
| Jan-5 | 21.40 | 21.07 | 21.97 | 20.86 |
| Jan-6 | 21.14 | 22.35 | 22.55 | 21.14 |
| Jan-7 | 22.50 | 23.46 | 24.10 | 22.17 |
Sarepta Therapeutics, Inc. Earnings
Sarepta Therapeutics, Inc. Earnings Report: Per Share Sarepta Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.
Sarepta Therapeutics, Inc. Forecast Revenue Growth
Sarepta Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Sarepta Therapeutics, Inc. and historical quarterly revenue growth:
-
Analysts estimate an earnings increase this quarter of $1.54 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.78 per share, and an increase next year of $0.24 per share.
* Sarepta Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.